Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	6/16/2003 2:41:16 AM
From: mopgcw	of 4974

Dendreon Corp Raises $26.7 M DOW JONES NEWSWIRES SEATTLE -- Dendreon Corp. (DNDN) raised $26.7 million in a stock sale, part of which will be used to develop the company's investigational cancer vaccine, Provenge. In a press release Friday, the Seattle drug maker said it sold 3.8 million shares at $7 a share to Baystar Capital, Mazama Capital Management and one additional existing Dendreon stockholder. The per-share sale price is at a 17% discount to Dendreon's closing Thursday price of $8.21, up 2 cents, or 0.2%. The company said it will use the proceeds to further the development of Provenge, a vaccine that treats androgen independent prostate cancer, and for general working capital purposes. That vaccine served as a catalyst to Dendreon's stock price surge on Wednesday, when the Food and Drug Administration said the company's Phase III Provenge trial could be used as a basis for approval.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next